ArticleJournal of human hypertension2026
Plasma aldosterone and long-term myocardial remodeling: a 10-year prospective analysis from the Tanushimaru Cohort.
Article in Journal of human hypertension, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
The renin-angiotensin-aldosterone system plays a central role in myocardial fibrosis and cardiac remodeling; however, longitudinal evidence regarding its association with long-term changes in left ventricular mass index (LVMI) in community-based populations remains limited. We investigated whether baseline plasma aldosterone concentration (PAC), plasma active renin concentration (ARC), and the aldosterone-to-renin ratio (ARR) were associated with 10-year LVMI progression in community-dwelling adults not receiving antihypertensive therapy. This longitudinal study included 539 participants (179 men and 360 women) from the Tanushimaru cohort in Japan who underwent health examinations in both 2009 and 2018. PAC and ARC were measured by radioimmunoassay, and LVMI was calculated using the Devereux formula. Multivariable logistic regression analyses were performed to evaluate the association between baseline PAC and LVMI progression over 10 years. Baseline PAC was not significantly associated with LVMI progression when analyzed as a continuous variable in fully adjusted models. Analyses of ARC and ARR also showed no significant associations with LVMI progression. Restricted cubic spline analysis suggested an increased risk at higher PAC, although the overall association did not reach statistical significance. Receiver operating characteristic analysis identified an exploratory cutoff value of 109.95 pg/mL. Participants with baseline PAC ≥ 110 pg/mL had a significantly increased risk of LVMI progression over 10 years after multivariable adjustment (odds ratio 1.86, 95% confidence interval 1.21-2.84; p = 0.0045). These findings suggest that higher PAC may be associated with myocardial structural remodeling in the general population.
Identifiers
42711371What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.